Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Robot-Assisted PCI: Corindus Plans Gradual Launch For Newly Cleared System

This article was originally published in The Gray Sheet

Executive Summary

The company announced 510(k) clearance of its CorPath 200 System July 25, calling it the “first and only” robot-assisted tool that allows percutaneous coronary interventions to be performed from an interventional cockpit.

You may also be interested in...



FDA Expands CorPath Robotic System Labeling To Radial PCIs

The company says as radial percutaneous coronary interventions continue to grow, FDA's 510(k) clearance gives more radiologists and interventional cardiologists access to a system that reduces their exposure to radiation.

Research In Brief

EyeBrain studies dyslexia in children of different languages. Robot PCI reduces radiation exposure. More research news.

News In Brief

Tornier doubles down on lower extremities with OrthoHelix purchase. Leica Biosystems buys Aperio. Siemens to acquire Penrith. More news briefs.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031435

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel